F22RS SGCR No. 55 (Student Media Fee)

TO PLACE A REFERENDUM BEFORE THE LOUISIANA STATE UNIVERSITY STUDENT BODY IN THE FALL 2022 ELECTION TO INCREASE THE SELF-ASSESSED STUDENT MEDIA FEE BY $2.75 TO BE DISTRIBUTED ALL STUDENT MEDIA ENTITIE

Risk Stratification and Early Oncologic Outcomes Following Robotic Prostatectomy

Results of this study suggest that robotic prostatectomy provides good cancer outcomes for clinically localized disease

SDSS-IV MaNGA: Variations in the N/O -- O/H relation bias metallicity gradient measurements

In this paper we use strong line calibrations of N/O and O/H in MaNGA spaxel data to explore the systematics introduced by variations in N/O on various strong-line metallicity diagnostics. We find radial variations in N/O at fixed O/H which correlate with total galaxy stellar-mass; and which can induce $\sim 40 \%$ systematic uncertainties in oxygen abundance gradients when nitrogen-dependent abundance calibrations are used. Empirically, we find that these differences are associated with variation in the local star formation efficiency, as predicted by recent chemical evolution models for galaxies, but we cannot rule out other processes such as radial migration and the accretion of passive dwarf galaxies also playing a role.Comment: 8 pages, 4 figures. Submitted to ApJL. All comments are welcom

Patient Navigators Connecting Patients to Community Resources to Improve Diabetes Outcomes

BACKGROUND: Despite the recognized importance of lifestyle modification in reducing risk of developing type 2 diabetes and in diabetes management, the use of available community resources by both patients and their primary care providers (PCPs) remains low. The patient navigator model, widely used in cancer care, may have the potential to link PCPs and community resources for reduction of risk and control of type 2 diabetes. In this study we tested the feasibility and acceptability of telephone-based nonprofessional patient navigation to promote linkages between the PCP office and community programs for patients with or at risk for diabetes. METHODS: This was a mixed-methods interventional prospective cohort study conducted between November 2012 and August 2013. We included adult patients with and at risk for type 2 diabetes from six primary care practices. Patient-level measures of glycemic control, diabetes care, and self-efficacy from medical records, and qualitative interview data on acceptability and feasibility, were used. RESULTS: A total of 179 patients participated in the study. Two patient navigators provided services over the phone, using motivational interviewing techniques. Patient navigators provided regular feedback to PCPs and followed up with the patients through phone calls. The patient navigators made 1028 calls, with an average of 6 calls per patient. At follow-up, reduction in HbA1c (7.8 ± 1.9% vs 7.2 ± 1.3%; P = .001) and improvement in patient self-efficacy (3.1 ± 0.8 vs 3.6 ± 0.7; P < .001) were observed. Qualitative analysis revealed uniformly positive feedback from providers and patients. CONCLUSIONS: The patient navigator model is a promising and acceptable strategy to link patient, PCP, and community resources for promoting lifestyle modification in people living with or at risk for type 2 diabetes

SDSS-IV MaNGA: Evidence for enriched accretion onto satellite galaxies in dense environments

We investigate the environmental dependence of the local gas-phase metallicity in a sample of star-forming galaxies from the MaNGA survey. Satellite galaxies with stellar masses in the range $910^{10.5} \, \mathrm{M_{\odot}}$) centrals are $\sim 0.1 \, \mathrm{dex}$ more metal rich than satellites of low-mass ($M_{*} < 10^{10} \, \mathrm{M_{\odot}}$) centrals, controlling for local stellar mass surface density and gas fraction. Fitting a gas-regulator model to the spaxel data, we are able to account for variations in the local gas fraction, stellar mass surface density and local escape velocity-dependent outflows. We find that the best explanation for the metallicity differences is the variation in the average metallicity of accreted gas between different environments that depends on the stellar mass of the dominant galaxies in each halo. This is interpreted as evidence for the exchange of enriched gas between galaxies in dense environments that is predicted by recent simulations

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.

Background &amp; aimsPatients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. Little is known about the association between disease duration and response to other biologic agents. We aimed to evaluate response of patients with CD or UC to vedolizumab, stratified by disease duration.MethodsWe analyzed data from a retrospective, multicenter, consortium of patients with CD (n = 650) or UC (n = 437) treated with vedolizumab from May 2014 through December 2016. Using time to event analyses, we compared rates of clinical remission, corticosteroid-free remission (CSFR), and endoscopic remission between patients with early-stage (≤2 years duration) and later-stage (&gt;2 years) CD or UC. We used Cox proportional hazards models to identify factors associated with outcomes.ResultsWithin 6 months initiation of treatment with vedolizumab, significantly higher proportions of patients with early-stage CD, vs later-stage CD, achieved clinical remission (38% vs 23%), CSFR (43% vs 14%), and endoscopic remission (29% vs 13%) (P &lt; .05 for all comparisons). After adjusting for disease-related factors including previous exposure to TNF antagonists, patients with early-stage CD were significantly more likely than patients with later-stage CD to achieve clinical remission (adjusted hazard ratio [aHR], 1.59; 95% CI, 1.02-2.49), CSFR (aHR, 3.39; 95% CI, 1.66-6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06-3.39). In contrast, disease duration was not a significant predictor of response among patients with UC.ConclusionsPatients with CD for 2 years or less are significantly more likely to achieve a complete response, CSFR, or endoscopic response to vedolizumab than patients with longer disease duration. Disease duration does not associate with response vedolizumab in patients with UC

Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study.

BACKGROUND Countries remain reluctant to adopt the 2012 World Health Organization recommendation for single low-dose (0.25 mg/kg) primaquine (SLD PQ) for Plasmodium falciparum transmission-blocking due to concerns over drug-related haemolysis risk, especially among glucose-6-phosphate dehydrogenase-deficient (G6PDd) people, without evidence demonstrating that it can be safely deployed in their settings. Pharmacovigilance methods provide a systematic way of collecting safety data and supporting the rollout of SLD PQ. METHODS The Primaquine Roll Out Monitoring Pharmacovigilance Tool (PROMPT), comprising: (1) a standardized form to support the surveillance of possible adverse events following SLD PQ treatment; (2) a patient information card to enhance awareness of known adverse drug reactions of SLD PQ use; and (3) a database compiling recorded information, was developed and piloted. Data on patient characteristics, malaria diagnosis and treatment are collected. Blood samples are taken to measure haemoglobin (Hb) and test for G6PD deficiency. Active follow-up includes a repeat Hb measurement and adverse event monitoring on or near day 7. A 13-month prospective pilot study in two hospital facilities in Swaziland alongside the introduction of SLD PQ generated preliminary evidence on the feasibility and acceptability of PROMPT. RESULTS PROMPT was well received by nurses as a simple, pragmatic approach to active surveillance of SLD PQ safety data. Of the 102 patients enrolled and administered SLD PQ, none were G6PDd. 93 (91.2 %) returned on or near day 7 for follow-up. Four (4.6 %) patients had falls in Hb ≥25 % from baseline, none of whom presented with signs or symptoms of anaemia. No patient's Hb fell below 7 g/dL and none required a blood transfusion. Of the 11 (11 %) patients who reported an adverse event over the study period, three were considered serious and included two deaths and one hospitalization; none were causally related to SLD PQ. Four non-serious adverse events were considered definitely, probably, or possibly related to SLD PQ. CONCLUSION Improved pharmacovigilance to monitor and promote the safety of the WHO recommendation is needed. The successful application of PROMPT demonstrates its potential as an important tool to rapidly generate locally acquired safety data and support pharmacovigilance in resource-limited settings

Miscellany

Art Literature Roy F. Powell Creditshttps://digitalcommons.georgiasouthern.edu/miscell/1001/thumbnail.jp